Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second IVIg dose in Guillain-Barré syndrome patients with poor prognosis
NL-OMON47229Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in Guillain-Barré syndrome (GBS) and acute inflammatory demyelinating polyneuropathy (AIDP) comparing Second IVIg course with Placebo (2 arms). Started Feb 2009; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
Guillain-Barré syndrome (GBS)acute inflammatory demyelinating polyneuropathy (AIDP)
Beyond the preview
Go deeper on NL-OMON47229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47229.